Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002)

BACKGROUND: Irinotecan hydrochloride and S-1, an oral fluoropyrimidine, have shown antitumor activity against advanced gastric cancer as single agents in phase I/II studies. The combination of irinotecan and S-1 (IRI-S) is also active against advanced gastric cancer. This study was conducted to comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Narahara, Hiroyuki, Iishi, Hiroyasu, Imamura, Hiroshi, Tsuburaya, Akira, Chin, Keisho, Imamoto, Haruhiko, Esaki, Taito, Furukawa, Hiroshi, Hamada, Chikuma, Sakata, Yuh
Formato: Texto
Lenguaje:English
Publicado: Springer Japan 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3056989/
https://www.ncbi.nlm.nih.gov/pubmed/21340666
http://dx.doi.org/10.1007/s10120-011-0009-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3056989/
https://www.ncbi.nlm.nih.gov/pubmed/21340666
http://dx.doi.org/10.1007/s10120-011-0009-5

Ejemplares similares